Novo Nordisk reports that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir (insulin detemir) in children with diabetes as young as one year old.

Levemir (insulin detemir) is a long-acting basal insulin for the treatment of diabetes. Levemir was launched in 2004 and is commercially available in 90 countries.

Source: Novo Nordisk